BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30610277)

  • 1. Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?
    Frick S; Müller D; Kullak-Ublick GA; Jetter A
    Eur J Clin Pharmacol; 2019 Mar; 75(3):335-342. PubMed ID: 30610277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
    Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
    Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
    Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
    Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.
    Simsek M; Meijer B; Mulder CJJ; van Bodegraven AA; de Boer NKH
    Ther Drug Monit; 2017 Dec; 39(6):584-588. PubMed ID: 29040228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients.
    Gilissen LP; Derijks LJ; Bos LP; Verhoeven HM; Bus PJ; Hooymans PM; Engels LG
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):705-10. PubMed ID: 15201586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
    Spencer E; Norris E; Williams C; Dubinsky MC
    Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.
    Lowry PW; Franklin CL; Weaver AL; Pike MG; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
    Gut; 2001 Nov; 49(5):665-70. PubMed ID: 11600469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
    Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
    Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.
    Boyle BM; Kappelman MD; Colletti RB; Baldassano RN; Milov DE; Crandall WV
    World J Gastroenterol; 2014 Jul; 20(27):9185-90. PubMed ID: 25083093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
    Beswick L; Friedman AB; Sparrow MP
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD.
    Kopylov U; Battat R; Benmassaoud A; Paradis-Surprenant L; Seidman EG
    Dig Dis Sci; 2015 Feb; 60(2):478-84. PubMed ID: 25236422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
    Wall GC; Muktar H; Effken C; Mahajan PB
    Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines.
    Waljee AK; Sauder K; Patel A; Segar S; Liu B; Zhang Y; Zhu J; Stidham RW; Balis U; Higgins PDR
    J Crohns Colitis; 2017 Jul; 11(7):801-810. PubMed ID: 28333183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases.
    Chapdelaine A; Mansour AM; Troyanov Y; Williamson DR; Doré M
    Clin Rheumatol; 2017 Jun; 36(6):1341-1348. PubMed ID: 28130685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
    Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
    Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.